Cargando…

Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2(+) breast cancer stem-like cells

BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with no effective standard therapy. Breast cancer stem-like cells (BCSCs) in primary TNBCs are reported to be responsible for metastatic spread of the disease and resistance to chemotherapy, but no availabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ly, Stanley, Anand, Vivek, El-Dana, Fouad, Nguyen, Khoa, Cai, Yiming, Cai, Shirong, Piwnica-Worms, Helen, Tripathy, Debasish, Sahin, Aysegul A, Andreeff, Michael, Battula, Venkata Lokesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970220/ https://www.ncbi.nlm.nih.gov/pubmed/33722905 http://dx.doi.org/10.1136/jitc-2020-001197

Ejemplares similares

Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
por: Zobel, Michael John, et al.
Publicado: (2020)

IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2(+) cancer stem cells
por: Battula, Venkata Lokesh, et al.
Publicado: (2017)

GD2 and GD3 synthase: novel drug targets for cancer therapy
por: Sphyris, Nathalie, et al.
Publicado: (2015)

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

Targeting NFκB signaling in GD2(+) BCSCs
por: Nguyen, Khoa, et al.
Publicado: (2017)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)

IMMU-11. LOCOREGIONAL DELIVERY OF TRANSIENT GD2 CAR T CELLS FOR SAFE AND EFFECTIVE TREATMENT OF DIPG
por: Foster, Jessica, et al.
Publicado: (2020)

IMMU-22. Safely targeting GD2 in thalamic diffuse midline glioma with mRNA CAR T cells
por: Foster, Jessica, et al.
Publicado: (2022)

Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer
por: Vantaku, Venkatrao, et al.
Publicado: (2017)

Correction: Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer
por: Vantaku, Venkatrao, et al.
Publicado: (2019)

Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
por: Evers, Mitchell, et al.
Publicado: (2021)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

GD2 expression in breast cancer
por: Orsi, Giulia, et al.
Publicado: (2017)

IMMU-17. USE OF MRNA FOR SAFE AND EFFECTIVE GD2-DIRECTED CAR T CELLS TO TREAT DIFFUSE MIDLINE GLIOMAS
por: Foster, Jessica, et al.
Publicado: (2021)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS
por: de Billy, Emmanuel, et al.
Publicado: (2020)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
por: Troschke-Meurer, Sascha, et al.
Publicado: (2023)

Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma
por: Aiken, Taylor J, et al.
Publicado: (2022)

Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants
por: Dondero, Alessandra, et al.
Publicado: (2021)

GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies
por: Nguyen, Khoa, et al.
Publicado: (2022)

Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype
por: Liang, Yuh-Jin, et al.
Publicado: (2017)

GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape
por: Caforio, Matteo, et al.
Publicado: (2021)

Upregulation of Ganglioside GD2 Synthase (GD2S), as a New Putative Cancer Stem Cell Marker in Breast Carcinomas
por: Mansoori, Maryam, et al.
Publicado: (2021)

Digital TDPAC with rare earth isotope $^{169}$Yb, $^{147}$Gd, and $^{149}$Gd in Yb and Gd Doped CeO$_{2}$ and $^{147}$Gd in GdBa$_{2}$ Cu$_{3}$ O$_{7−\delta}$
por: Roeder, Jens, et al.
Publicado: (2011)

IMMU-18. TARGETING GD2 IN THALAMIC DIFFUSE MIDLINE GLIOMA WITH TRANSIENT MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2023)

GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer
por: Galan, Alba, et al.
Publicado: (2023)

Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
por: Erber, Ramona, et al.
Publicado: (2021)

Self-patterning Gd nano-fibers in Mg-Gd alloys
por: Li, Yangxin, et al.
Publicado: (2016)

Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells
por: Yanagisawa, Makoto, et al.
Publicado: (2011)

The effects of three different contrast agents (Gd-BOPTA, Gd-DTPA, and Gd-DOTA) on brachial plexus magnetic resonance imaging
por: Zhang, Xiaojing, et al.
Publicado: (2021)

Effects of Static Magnetic Field on Compression Properties of Mg-Al-Gd Alloys Containing Gd-Rich Ferromagnetic Phase
por: Cai, Qi, et al.
Publicado: (2020)

Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis
por: Le, Phuong M., et al.
Publicado: (2018)

Giant exchange coupling and field-induced slow relaxation of magnetization in Gd(2)@C(79)N with a single-electron Gd–Gd bond
por: Velkos, G., et al.
Publicado: (2018)

Bone marrow stromal cells induce an ALDH(+) stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway
por: Yuan, Bin, et al.
Publicado: (2020)

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial
por: Flaadt, Tim, et al.
Publicado: (2023)

O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells
por: Cheng, Jing-Yan, et al.
Publicado: (2022)

Measurement of the neutron capture cross section for $^{155}$Gd and $^{157}$Gd for Nuclear Technology
por: Lo Meo, Sergio, et al.
Publicado: (2015)

Ganglioside GD3 synthase (GD3S), a novel cancer drug target
por: Liu, Jinyi, et al.
Publicado: (2018)

Dinutuximab beta for neuroblastoma
Publicado: (2020)

Internal dose assessment of (148)Gd using isotope ratios of gamma-emitting (146)Gd or (153)Gd in accidently released spallation target particles
por: Rääf, C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vkkktg7prsaumpmeqd2nekeaau